子宫内膜异位症术后应用GnRH-α和孕三烯酮疗效观察

Clinical efficacy observation of GnRH-α and gestrinone in consolidation therapy after operation of endometriosis

目的观察促性腺激素释放激素激动剂(GnRH-α)和孕三烯酮应用于盆腔子宫内膜异位症术后患者巩固治疗的疗效。方法选择2005年1月～2008年1月在中国石油中心医院进行保守性手术治疗并经病理证实为子宫内膜异位症的患者80例,随机分成两组。GnRH-α组45例,给予GnRH-α3.75mg肌注,每28天1次,于月经来潮5d内开始;孕三烯酮组35例,给予孕三烯酮2.5mg口服,每周2次,于月经来潮第1天开始。疗程3～6个月。定期随访。结果 GnRH-α组及孕三烯酮组经治疗后与治疗前相比,各组由子宫内膜异位症引起的痛经等疼痛症状得到明显改善(P<0.05)。随访结果显示,GnRH-α组和孕三烯酮组症状完全缓解率分别为88.9%和85.7%,两组复发率分别为4.4%和5.7%。两组疗效及复发率比较差异无统计学意义(P>0.05)。在副反应方面,GnRH-α组显著小于孕三烯酮组。结论 GnRH-α与孕三烯酮用于盆腔子宫内膜异位症手术后巩固治疗安全、有效、不良反应轻。

Objective To observe the clinical efficacy of GnRH-α and gestrinone in consolidation therapy after opera- tion of endometriosis. Methods Eighty cases undergoing conservative surgery and diagnosed as pelvic endometriosis by pathological examination from January 2005 to January 2008 were divided into 2 groups randomly. 45 cases in GnRH-α group were injected GnRH-α 3.75 mg each time per 28 days from the first-fifth day of menstruation. 35 cases in gestrinone group took gestrinone 2.5 mg per day, twice a week from the first day of menstruation. Results The rates of dysmenorrhea and other painful systems in two groups after treatment were significantly lower than those before treat- ment （P 〈 0.05）. Followed up results showed that complete remission rates in GnRH-α group and gestrinone group were 88.9% and 85.7%, respectively. The relapse rates in GnRH-ct group and gestrinone group were 4.4% and 5.7%, re- spectively. There was no significant difference （P 〉 0.05）. The incidence of adverse reaction in GnRH-α group was significantly lower than that in gestrinone group. Conclusion Application of GnRH-α and gestrinone in consolidation therapy after operation of endometriosis is safe and effective, without serve adverse reactions.